Latest Trovagene Inc. Stories
SAN DIEGO, Oct. 29, 2014 /PRNewswire/ -- Trovagene, Inc.
Prospective blinded study demonstrates ability to accurately determine mutational status and monitor response to BRAF inhibitor therapy from urinary cell-free DNA SAN DIEGO, Oct.
BIO Investor Forum to be held October 7-8 in San Francisco, California SAN DIEGO, Oct. 6, 2014 /PRNewswire/ -- Trovagene, Inc.
BRAF V600E assay improves determination of mutational status and allows monitoring of treatment response SAN DIEGO, Oct.
Additional Study Focuses on the Detection and Quantitative Monitoring of EGFR Mutations in Lung Cancer Patients SAN DIEGO, Sept.
SAN DIEGO, Sept.
Data from Urinary Cell-free DNA Presented at Next Generation Dx Summit WASHINGTON, Aug. 26, 2014 /PRNewswire/ -- Trovagene, Inc.
SEATTLE, Aug. 25, 2014 /PRNewswire/ -- Trovagene, Inc.
SAN DIEGO, Aug. 20, 2014 /PRNewswire/ -- Trovagene, Inc.
SAN DIEGO, Aug. 12, 2014 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, announced today that K.
- The act of burning, scorching, or heating to dryness; the state or being thus heated or dried.
- In medicine, cauterization.